Clinical Trial

Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
primary purpose：Observe the pathological complete response rate (PCR) of postoperative tumor tissue resection and evaluate the safety of the treatment process.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-05-26; most recent amendment 2024-10-15.
Status change: Recruiting → Active, Not Recruiting 2023-12-27
Trial Details
NCT Number NCT05400070
Lead Sponsor Tang-Du Hospital
Conditions Sintilimab, Lung Cancer, Anlotinib, Chemotherapy
Enrollment 45 participants
Start Date 2021-03-01
Primary Completion 2023-12-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-10-18